In a phase II trial, risovalisib yielded a 35% objective response rate in patients with recurrent or persistent PIK3CA -mutated ovarian clear cell carcinoma.
Among patients who underwent resection of a large (≥ 2 cm) brain metastasis, postoperative fractionated stereotactic radiosurgery (SRS) improved surgical bed control compared with single-fraction SRS without an apparent increase in toxicity. This was according to findings from the multicenter phase III Alliance A071801 trial.
Scientists have reconstructed how acute myeloid leukemia (AML) develops over the decades before diagnosis, showing that in two-thirds of cases, the first cancer-driving mutation had been acquired before the age of 20—more than 50 years before the usual age of diagnosis.
Neoadjuvant treatment with the immune-directed bispecific antibody rilvegostomig plus the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (RT-DXd) demonstrated “promising” activity with mostly low-grade adverse events in patients with immune-positive, ERBB2-negative early breast cancer, according to findings from the adaptively randomized, multicenter phase II I-SPY2.2 platform trial.